Takeda Pharmaceutical (TAK) Total Non-Current Liabilities (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Total Non-Current Liabilities of $33.5 billion for Q2 2026, down 2.44% year-over-year from $34.3 billion in Q2 2025, and little changed quarter-over-quarter from $33.5 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $33.5 billion for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 2.44% year-over-year to $33.5 billion; the TTM figure through Jun 2026 stood at $33.5 billion (down 2.44% YoY), while the FY2026 annual figure was $34.9 billion, up 10.52% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $33.5 billion, roughly flat from $33.5 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $46.0 billion in Q1 2022, with the low at $31.5 billion in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $36.4 billion (2022), against an average of $36.9 billion.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities dropped 26.29% in 2022, then rose 6.25% in 2026.
- Takeda Pharmaceutical's Total Non-Current Liabilities stood at $36.0 billion in 2022, then slipped by 2.42% to $35.2 billion in 2023, then grew by 4.55% to $36.8 billion in 2024, then retreated by 8.91% to $33.5 billion in 2025, then climbed by 0.02% to $33.5 billion in 2026.
- Business Quant data shows TAK's Total Non-Current Liabilities at $33.5 billion in Q2 2026, $33.5 billion in Q1 2026, and $33.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | 2.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.50 Bn |
| Mar 31, 2026 | 33.47 Bn |
| Dec 31, 2025 | 33.49 Bn |
| Sep 30, 2025 | 35.28 Bn |
| Jun 30, 2025 | 34.34 Bn |
| Mar 31, 2025 | 31.50 Bn |
| Dec 31, 2024 | 36.77 Bn |
| Sep 30, 2024 | 35.29 Bn |
| Jun 30, 2024 | 38.31 Bn |
| Mar 31, 2024 | 37.26 Bn |
| Dec 31, 2023 | 35.17 Bn |
| Sep 30, 2023 | 37.62 Bn |
| Jun 30, 2023 | 39.18 Bn |
| Mar 31, 2023 | 38.72 Bn |
| Dec 31, 2022 | 36.04 Bn |
| Sep 30, 2022 | 39.70 Bn |
| Jun 30, 2022 | 43.16 Bn |
| Mar 31, 2022 | 46.03 Bn |
| Dec 31, 2021 | 48.89 Bn |
| Sep 30, 2021 | 48.30 Bn |